Piramal Pharma

Historical price data

Piramal Pharma is a leading, diversified global pharmaceutical company headquartered in India, structured into three core business verticals: Contract Development and Manufacturing (CDMO), Complex Hospital Generics, and Consumer Healthcare. The company leverages its expertise in complex chemistry and manufacturing to serve a global client base, including major pharmaceutical innovators. Its strategic focus is on high-growth, niche segments like injectables, oncology, and critical care, supported by a network of over 15 manufacturing facilities worldwide. The company was demerged from Piramal Enterprises and listed separately in 2022 to unlock value and drive focused growth.

Expertise in complex chemistry, including High-Potency API (HPAPI) manufacturing, peptide synthesis, continuous flow chemistry, and development of complex formulations like sterile injectables.

Total raised: $490M

Piramal Pharma competes with global CDMOs like Lonza and Catalent, specialized generic players like Hikma, and Indian consumer giants. Its differentiation lies in integrated service offerings, deep expertise in complex chemistry, and a diversified business model that mitigates sector-specific downturns.